APO Research
Talk to an analyst

APO RESEARCH · REPORT

PD-1&PD-L1 Immunotherapy

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global PD-1&PD-L1 Immunotherapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026198 pages

Choose your research edition.

Industry ResearchPD-1&PD-L1 Immunotherapy Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-1&PD-L1 Immunotherapy Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal PD-1&PD-L1 Immunotherapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-1&PD-L1 Immunotherapy Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-1&PD-L1 Immunotherapy Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global PD-1&PD-L1 Immunotherapy market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for PD-1&PD-L1 Immunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PD-1&PD-L1 Immunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PD-1&PD-L1 Immunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for PD-1&PD-L1 Immunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of PD-1&PD-L1 Immunotherapy include Sanofi S.A., Novartis AG, Merck & Co., Inc., Eli Lilly & Company, Pfizer Inc., Jiangsu HengRui Medicine Co., Ltd., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc. and Innovent Biologics, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global PD-1&PD-L1 Immunotherapy market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PD-1&PD-L1 Immunotherapy and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PD-1&PD-L1 Immunotherapy sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PD-1&PD-L1 Immunotherapy market size, projected growth trends, production technologies, key applications, and end-use industries.

PD-1&PD-L1 Immunotherapy Segment by Company

Sanofi S.A.

Novartis AG

Merck & Co., Inc.

Eli Lilly & Company

Pfizer Inc.

Jiangsu HengRui Medicine Co., Ltd.

GlaxoSmithKline plc

Regeneron Pharmaceuticals Inc.

Innovent Biologics, Inc.

F. Hoffmann-La Roche Ltd

Chia Tai Tianqing Pharmaceutical Group Co. Ltd.

Bristol-Myers Squibb Company

BeiGene, Ltd.

AstraZeneca Plc

PD-1&PD-L1 Immunotherapy Segment by Type

PD-1 Inhibitors

PD-L1 Inhibitors

PD-1&PD-L1 Immunotherapy Segment by Application

Non-Small Cell Lung Cancer

Hepatocellular Carcinoma

Urothelial Carcinoma

Esophageal Cancer

Small Cell Lung Cancer

Others

PD-1&PD-L1 Immunotherapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1&PD-L1 Immunotherapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-1&PD-L1 Immunotherapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1&PD-L1 Immunotherapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PD-1&PD-L1 Immunotherapy market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of PD-1&PD-L1 Immunotherapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of PD-1&PD-L1 Immunotherapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of PD-1&PD-L1 Immunotherapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. PD-1&PD-L1 Immunotherapy Industry Trends Table 2. PD-1&PD-L1 Immunotherapy Industry Drivers Table 3. PD-1&PD-L1 Immunotherapy Industry Opportunities and Challenges Table 4. PD-1&PD-L1 Immunotherapy Industry Restraints Table 5. Global PD-1&PD-L1 Immunotherapy Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Manufacturers (2021-2026) Table 7. Global PD-1&PD-L1 Immunotherapy Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Manufacturers Table 9. Global PD-1&PD-L1 Immunotherapy Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global PD-1&PD-L1 Immunotherapy Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global PD-1&PD-L1 Immunotherapy Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global PD-1&PD-L1 Immunotherapy Manufacturers, Product Type & Application Table 13. Global PD-1&PD-L1 Immunotherapy Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global PD-1&PD-L1 Immunotherapy by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of PD-1 Inhibitors Table 17. Major Manufacturers of PD-L1 Inhibitors Table 18. Global PD-1&PD-L1 Immunotherapy Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (K Units) Table 20. Global PD-1&PD-L1 Immunotherapy Sales by Type (2027-2032) & (K Units) Table 21. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2021-2026) Table 22. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2027-2032) Table 23. Global PD-1&PD-L1 Immunotherapy Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global PD-1&PD-L1 Immunotherapy Revenue by Type (2021-2026) & (K Units) Table 25. Global PD-1&PD-L1 Immunotherapy Revenue by Type (2027-2032) & (K Units) Table 26. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2021-2026) Table 27. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Non-Small Cell Lung Cancer Table 29. Major Manufacturers of Hepatocellular Carcinoma Table 30. Major Manufacturers of Urothelial Carcinoma Table 31. Major Manufacturers of Esophageal Cancer Table 32. Major Manufacturers of Small Cell Lung Cancer Table 33. Major Manufacturers of Others Table 34. Global PD-1&PD-L1 Immunotherapy Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (K Units) Table 36. Global PD-1&PD-L1 Immunotherapy Sales by Application (2027-2032) & (K Units) Table 37. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2021-2026) Table 38. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2027-2032) Table 39. Global PD-1&PD-L1 Immunotherapy Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global PD-1&PD-L1 Immunotherapy Revenue by Application (2021-2026) & (K Units) Table 41. Global PD-1&PD-L1 Immunotherapy Revenue by Application (2027-2032) & (K Units) Table 42. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2021-2026) Table 43. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2027-2032) Table 44. Global PD-1&PD-L1 Immunotherapy Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global PD-1&PD-L1 Immunotherapy Sales by Region (2021-2026) & (K Units) Table 46. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2021-2026) Table 47. Global PD-1&PD-L1 Immunotherapy Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global PD-1&PD-L1 Immunotherapy Sales Forecasted Market Share by Region (2027-2032) Table 49. North America PD-1&PD-L1 Immunotherapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026) & (K Units) Table 51. North America PD-1&PD-L1 Immunotherapy Sales by Country (2027-2032) & (K Units) Table 52. Europe PD-1&PD-L1 Immunotherapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026) & (K Units) Table 54. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific PD-1&PD-L1 Immunotherapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific PD-1&PD-L1 Immunotherapy Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Country (2027-2032) & (K Units) Table 61. Global PD-1&PD-L1 Immunotherapy Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global PD-1&PD-L1 Immunotherapy Revenue by Region (2021-2026) & (US$ Million) Table 63. Global PD-1&PD-L1 Immunotherapy Revenue by Region (2027-2032) & (US$ Million) Table 64. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2021-2026) Table 65. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2027-2032) Table 66. Sanofi S.A. Company Information Table 67. Sanofi S.A. Business Overview Table 68. Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Portfolio Table 70. Sanofi S.A. Recent Development Table 71. Novartis AG Company Information Table 72. Novartis AG Business Overview Table 73. Novartis AG PD-1&PD-L1 Immunotherapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Novartis AG PD-1&PD-L1 Immunotherapy Product Portfolio Table 75. Novartis AG Recent Development Table 76. Merck & Co., Inc. Company Information Table 77. Merck & Co., Inc. Business Overview Table 78. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Portfolio Table 80. Merck & Co., Inc. Recent Development Table 81. Eli Lilly & Company Company Information Table 82. Eli Lilly & Company Business Overview Table 83. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Portfolio Table 85. Eli Lilly & Company Recent Development Table 86. Pfizer Inc. Company Information Table 87. Pfizer Inc. Business Overview Table 88. Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Portfolio Table 90. Pfizer Inc. Recent Development Table 91. Jiangsu HengRui Medicine Co., Ltd. Company Information Table 92. Jiangsu HengRui Medicine Co., Ltd. Business Overview Table 93. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio Table 95. Jiangsu HengRui Medicine Co., Ltd. Recent Development Table 96. GlaxoSmithKline plc Company Information Table 97. GlaxoSmithKline plc Business Overview Table 98. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Portfolio Table 100. GlaxoSmithKline plc Recent Development Table 101. Regeneron Pharmaceuticals Inc. Company Information Table 102. Regeneron Pharmaceuticals Inc. Business Overview Table 103. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Portfolio Table 105. Regeneron Pharmaceuticals Inc. Recent Development Table 106. Innovent Biologics, Inc. Company Information Table 107. Innovent Biologics, Inc. Business Overview Table 108. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Portfolio Table 110. Innovent Biologics, Inc. Recent Development Table 111. F. Hoffmann-La Roche Ltd Company Information Table 112. F. Hoffmann-La Roche Ltd Business Overview Table 113. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Portfolio Table 115. F. Hoffmann-La Roche Ltd Recent Development Table 116. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Information Table 117. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Business Overview Table 118. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio Table 120. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Development Table 121. Bristol-Myers Squibb Company Company Information Table 122. Bristol-Myers Squibb Company Business Overview Table 123. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Portfolio Table 125. Bristol-Myers Squibb Company Recent Development Table 126. BeiGene, Ltd. Company Information Table 127. BeiGene, Ltd. Business Overview Table 128. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio Table 130. BeiGene, Ltd. Recent Development Table 131. AstraZeneca Plc Company Information Table 132. AstraZeneca Plc Business Overview Table 133. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Portfolio Table 135. AstraZeneca Plc Recent Development Table 136. Key Raw Materials Table 137. Raw Materials Key Suppliers Table 138. PD-1&PD-L1 Immunotherapy Distributors List Table 139. PD-1&PD-L1 Immunotherapy Customers List Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. PD-1&PD-L1 Immunotherapy Product Image Figure 2. Global PD-1&PD-L1 Immunotherapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PD-1&PD-L1 Immunotherapy Market Size (2021-2032) & (US$ Million) Figure 4. Global PD-1&PD-L1 Immunotherapy Sales (2021-2032) & (K Units) Figure 5. Global PD-1&PD-L1 Immunotherapy Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 PD-1&PD-L1 Immunotherapy Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. PD-1 Inhibitors Image Figure 9. PD-L1 Inhibitors Image Figure 10. Global PD-1&PD-L1 Immunotherapy Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global PD-1&PD-L1 Immunotherapy Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2021-2032) Figure 13. Global PD-1&PD-L1 Immunotherapy Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global PD-1&PD-L1 Immunotherapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2021-2032) Figure 16. Non-Small Cell Lung Cancer Image Figure 17. Hepatocellular Carcinoma Image Figure 18. Urothelial Carcinoma Image Figure 19. Esophageal Cancer Image Figure 20. Small Cell Lung Cancer Image Figure 21. Others Image Figure 22. Global PD-1&PD-L1 Immunotherapy Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global PD-1&PD-L1 Immunotherapy Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2021-2032) Figure 25. Global PD-1&PD-L1 Immunotherapy Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global PD-1&PD-L1 Immunotherapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2021-2032) Figure 28. North America PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2021-2032) Figure 30. U.S. PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2021-2032) Figure 35. Germany PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2021-2032) Figure 42. China PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2021-2032) Figure 50. Brazil PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile PD-1&PD-L1 Immunotherapy Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global PD-1&PD-L1 Immunotherapy Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Figure 61. North America PD-1&PD-L1 Immunotherapy Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Figure 63. Europe PD-1&PD-L1 Immunotherapy Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific PD-1&PD-L1 Immunotherapy Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa PD-1&PD-L1 Immunotherapy Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. PD-1&PD-L1 Immunotherapy Value Chain Figure 69. Manufacturing Cost Structure Figure 70. PD-1&PD-L1 Immunotherapy Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • PD-1 Inhibitors
  • PD-L1 Inhibitors
Applications
  • Non-Small Cell Lung Cancer
  • Hepatocellular Carcinoma
  • Urothelial Carcinoma
  • Esophageal Cancer
  • Small Cell Lung Cancer
  • Others
Companies covered
  • Sanofi S.A.
  • Novartis AG
  • Merck & Co., Inc.
  • Eli Lilly & Company
  • Pfizer Inc.
  • Jiangsu HengRui Medicine Co., Ltd.
  • GlaxoSmithKline plc
  • Regeneron Pharmaceuticals Inc.
  • Innovent Biologics, Inc.
  • F. Hoffmann-La Roche Ltd
  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
  • Bristol-Myers Squibb Company
  • BeiGene, Ltd.
  • AstraZeneca Plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global PD-1&PD-L1 Immunotherapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global PD-1&PD-L1 Immunotherapy Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global PD-1&PD-L1 Immunotherapy Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global PD-1&PD-L1 Immunotherapy Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global PD-1&PD-L1 Immunotherapy Market Dynamics
  1. 2.1 PD-1&PD-L1 Immunotherapy Industry Trends
  2. 2.2 PD-1&PD-L1 Immunotherapy Industry Drivers
  3. 2.3 PD-1&PD-L1 Immunotherapy Industry Opportunities and Challenges
  4. 2.4 PD-1&PD-L1 Immunotherapy Industry Restraints
3 PD-1&PD-L1 Immunotherapy Market by Manufacturers
  1. 3.1 Global PD-1&PD-L1 Immunotherapy Revenue by Manufacturers (2021-2026)
  2. 3.2 Global PD-1&PD-L1 Immunotherapy Sales by Manufacturers (2021-2026)
  3. 3.3 Global PD-1&PD-L1 Immunotherapy Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global PD-1&PD-L1 Immunotherapy Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global PD-1&PD-L1 Immunotherapy Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global PD-1&PD-L1 Immunotherapy Manufacturers, Product Type & Application
  7. 3.7 Global PD-1&PD-L1 Immunotherapy Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global PD-1&PD-L1 Immunotherapy Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 PD-1&PD-L1 Immunotherapy Players Market Share by Revenue in 2025
  11. 3.8.3 2025 PD-1&PD-L1 Immunotherapy Tier 1, Tier 2, and Tier 3
4 PD-1&PD-L1 Immunotherapy Market by Type
  1. 4.1 PD-1&PD-L1 Immunotherapy Type Introduction
  2. 4.1.1 PD-1 Inhibitors
  3. 4.1.2 PD-L1 Inhibitors
  4. 4.2 Global PD-1&PD-L1 Immunotherapy Sales by Type
  5. 4.2.1 Global PD-1&PD-L1 Immunotherapy Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global PD-1&PD-L1 Immunotherapy Sales by Type (2021-2032)
  7. 4.2.3 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2021-2032)
  8. 4.3 Global PD-1&PD-L1 Immunotherapy Revenue by Type
  9. 4.3.1 Global PD-1&PD-L1 Immunotherapy Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global PD-1&PD-L1 Immunotherapy Revenue by Type (2021-2032)
  11. 4.3.3 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2021-2032)
5 PD-1&PD-L1 Immunotherapy Market by Application
  1. 5.1 PD-1&PD-L1 Immunotherapy Application Introduction
  2. 5.1.1 Non-Small Cell Lung Cancer
  3. 5.1.2 Hepatocellular Carcinoma
  4. 5.1.3 Urothelial Carcinoma
  5. 5.1.4 Esophageal Cancer
  6. 5.1.5 Small Cell Lung Cancer
  7. 5.1.6 Others
  8. 5.2 Global PD-1&PD-L1 Immunotherapy Sales by Application
  9. 5.2.1 Global PD-1&PD-L1 Immunotherapy Sales by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global PD-1&PD-L1 Immunotherapy Sales by Application (2021-2032)
  11. 5.2.3 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2021-2032)
  12. 5.3 Global PD-1&PD-L1 Immunotherapy Revenue by Application
  13. 5.3.1 Global PD-1&PD-L1 Immunotherapy Revenue by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global PD-1&PD-L1 Immunotherapy Revenue by Application (2021-2032)
  15. 5.3.3 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2021-2032)
6 Global PD-1&PD-L1 Immunotherapy Sales by Region
  1. 6.1 Global PD-1&PD-L1 Immunotherapy Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PD-1&PD-L1 Immunotherapy Sales by Region (2021-2032)
  3. 6.2.1 Global PD-1&PD-L1 Immunotherapy Sales by Region (2021-2026)
  4. 6.2.2 Global PD-1&PD-L1 Immunotherapy Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America PD-1&PD-L1 Immunotherapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America PD-1&PD-L1 Immunotherapy Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe PD-1&PD-L1 Immunotherapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe PD-1&PD-L1 Immunotherapy Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific PD-1&PD-L1 Immunotherapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific PD-1&PD-L1 Immunotherapy Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global PD-1&PD-L1 Immunotherapy Revenue by Region
  1. 7.1 Global PD-1&PD-L1 Immunotherapy Revenue by Region
  2. 7.1.1 Global PD-1&PD-L1 Immunotherapy Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global PD-1&PD-L1 Immunotherapy Revenue by Region (2021-2026)
  4. 7.1.3 Global PD-1&PD-L1 Immunotherapy Revenue by Region (2027-2032)
  5. 7.1.4 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America PD-1&PD-L1 Immunotherapy Revenue (2021-2032)
  8. 7.2.2 North America PD-1&PD-L1 Immunotherapy Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe PD-1&PD-L1 Immunotherapy Revenue (2021-2032)
  11. 7.3.2 Europe PD-1&PD-L1 Immunotherapy Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific PD-1&PD-L1 Immunotherapy Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific PD-1&PD-L1 Immunotherapy Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa PD-1&PD-L1 Immunotherapy Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa PD-1&PD-L1 Immunotherapy Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi S.A.
  2. 8.1.1 Sanofi S.A. Company Information
  3. 8.1.2 Sanofi S.A. Business Overview
  4. 8.1.3 Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Portfolio
  6. 8.1.5 Sanofi S.A. Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG PD-1&PD-L1 Immunotherapy Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Merck & Co., Inc.
  14. 8.3.1 Merck & Co., Inc. Company Information
  15. 8.3.2 Merck & Co., Inc. Business Overview
  16. 8.3.3 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
  18. 8.3.5 Merck & Co., Inc. Recent Developments
  19. 8.4 Eli Lilly & Company
  20. 8.4.1 Eli Lilly & Company Company Information
  21. 8.4.2 Eli Lilly & Company Business Overview
  22. 8.4.3 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Portfolio
  24. 8.4.5 Eli Lilly & Company Recent Developments
  25. 8.5 Pfizer Inc.
  26. 8.5.1 Pfizer Inc. Company Information
  27. 8.5.2 Pfizer Inc. Business Overview
  28. 8.5.3 Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
  30. 8.5.5 Pfizer Inc. Recent Developments
  31. 8.6 Jiangsu HengRui Medicine Co., Ltd.
  32. 8.6.1 Jiangsu HengRui Medicine Co., Ltd. Company Information
  33. 8.6.2 Jiangsu HengRui Medicine Co., Ltd. Business Overview
  34. 8.6.3 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
  36. 8.6.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments
  37. 8.7 GlaxoSmithKline plc
  38. 8.7.1 GlaxoSmithKline plc Company Information
  39. 8.7.2 GlaxoSmithKline plc Business Overview
  40. 8.7.3 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Portfolio
  42. 8.7.5 GlaxoSmithKline plc Recent Developments
  43. 8.8 Regeneron Pharmaceuticals Inc.
  44. 8.8.1 Regeneron Pharmaceuticals Inc. Company Information
  45. 8.8.2 Regeneron Pharmaceuticals Inc. Business Overview
  46. 8.8.3 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
  48. 8.8.5 Regeneron Pharmaceuticals Inc. Recent Developments
  49. 8.9 Innovent Biologics, Inc.
  50. 8.9.1 Innovent Biologics, Inc. Company Information
  51. 8.9.2 Innovent Biologics, Inc. Business Overview
  52. 8.9.3 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
  54. 8.9.5 Innovent Biologics, Inc. Recent Developments
  55. 8.10 F. Hoffmann-La Roche Ltd
  56. 8.10.1 F. Hoffmann-La Roche Ltd Company Information
  57. 8.10.2 F. Hoffmann-La Roche Ltd Business Overview
  58. 8.10.3 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Portfolio
  60. 8.10.5 F. Hoffmann-La Roche Ltd Recent Developments
  61. 8.11 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
  62. 8.11.1 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Information
  63. 8.11.2 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Business Overview
  64. 8.11.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
  66. 8.11.5 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Developments
  67. 8.12 Bristol-Myers Squibb Company
  68. 8.12.1 Bristol-Myers Squibb Company Company Information
  69. 8.12.2 Bristol-Myers Squibb Company Business Overview
  70. 8.12.3 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Portfolio
  72. 8.12.5 Bristol-Myers Squibb Company Recent Developments
  73. 8.13 BeiGene, Ltd.
  74. 8.13.1 BeiGene, Ltd. Company Information
  75. 8.13.2 BeiGene, Ltd. Business Overview
  76. 8.13.3 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
  78. 8.13.5 BeiGene, Ltd. Recent Developments
  79. 8.14 AstraZeneca Plc
  80. 8.14.1 AstraZeneca Plc Company Information
  81. 8.14.2 AstraZeneca Plc Business Overview
  82. 8.14.3 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Portfolio
  84. 8.14.5 AstraZeneca Plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PD-1&PD-L1 Immunotherapy Value Chain Analysis
  2. 9.1.1 PD-1&PD-L1 Immunotherapy Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PD-1&PD-L1 Immunotherapy Production Mode & Process
  6. 9.2 PD-1&PD-L1 Immunotherapy Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PD-1&PD-L1 Immunotherapy Distributors
  9. 9.2.3 PD-1&PD-L1 Immunotherapy Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst